75 related articles for article (PubMed ID: 38433181)
1. Trastuzumab deruxtecan in breast cancer.
Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
4. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil A; Spitzmüller A; Brieu N; Haneder S; Shumilov A; Meier A; Cecchi F; Barkell A; Harder N; Mittermaier K; Hidalgo-Sastre A; Alleze R; Schick M; Schmidt G; Sade H; Tsuchihashi Z; Suto F; Gustavson M; Barrett JC; Carroll D
Sci Rep; 2024 May; 14(1):12129. PubMed ID: 38802399
[TBL] [Abstract][Full Text] [Related]
5. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
6. Deep learning-assisted monitoring of trastuzumab efficacy in HER2-Overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers.
Kim J; Son HY; Lee S; Rho HW; Kim R; Jeong H; Park C; Mun B; Moon Y; Jeong E; Lim EK; Haam S
Biosens Bioelectron; 2024 Aug; 258():116347. PubMed ID: 38723332
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Hattori M; Honma N; Nagai S; Narui K; Shigechi T; Ozaki Y; Yoshida M; Sakatani T; Sasaki E; Tanabe Y; Tsurutani J; Takano T; Saji S; Masuda S; Horii R; Tsuda H; Yamaguchi R; Toyama T; Yamauchi C; Toi M; Yamamoto Y
Breast Cancer; 2024 May; 31(3):335-339. PubMed ID: 38433181
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
12. [New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Minot-This MS; Bellesoeur A
Bull Cancer; 2021 Sep; 108(9):783-784. PubMed ID: 34144792
[No Abstract] [Full Text] [Related]
13. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
15. A novel system to provide information via online YouTube videos and an evaluation of current online information about hereditary breast cancer.
Iesato A; Fushimi A; Tahara R; Terada M; Iwase M; Kawamura C; Yamashita N
Breast Cancer; 2024 Jan; 31(1):63-74. PubMed ID: 37995024
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
